問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳尹愷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳尹愷

List

11Cases

2024-09-15 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2016-12-13 - 2022-05-05

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-08-01 - 2020-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

2015-10-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-01-02 - 2029-06-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-01-01 - 2017-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2025-05-01 - 2028-02-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-01-15 - 2020-02-28

Phase II

An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Condition/Disease

    Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-03-19 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB